| Literature DB >> 31394204 |
Francisco Q Gonçalves1, João P Lopes1, Henrique B Silva1, Cristina Lemos1, António C Silva1, Nélio Gonçalves1, Ângelo R Tomé1, Samira G Ferreira1, Paula M Canas1, Daniel Rial1, Paula Agostinho2, Rodrigo A Cunha3.
Abstract
Adenosine A2A receptors (A2AR) overfunction causes synaptic and memory dysfunction in early Alzheimer's disease (AD). In a β-amyloid (Aβ1-42)-based model of early AD, we now unraveled that this involves an increased synaptic release of ATP coupled to an increased density and activity of ecto-5'-nucleotidase (CD73)-mediated formation of adenosine selectively activating A2AR. Thus, CD73 inhibition with α,β-methylene-ADP impaired long-term potentiation (LTP) in mouse hippocampal slices, which is occluded upon previous superfusion with the A2AR antagonist SCH58261. Furthermore, α,β-methylene-ADP did not alter LTP amplitude in global A2AR knockout (KO) and in forebrain neuron-selective A2AR-KO mice, but inhibited LTP amplitude in astrocyte-selective A2AR-KO mice; this shows that CD73-derived adenosine solely acts on neuronal A2AR. In agreement with the concept that ATP is a danger signal in the brain, ATP release from nerve terminals is increased after intracerebroventricular Aβ1-42 administration, together with CD73 and A2AR upregulation in hippocampal synapses. Importantly, this increased CD73 activity is critically required for Aβ1-42 to impair synaptic plasticity and memory since Aβ1-42-induced synaptic and memory deficits were eliminated in CD73-KO mice. These observations establish a key regulatory role of CD73 activity over neuronal A2AR and imply CD73 as a novel target for modulation of early AD.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31394204 DOI: 10.1016/j.nbd.2019.104570
Source DB: PubMed Journal: Neurobiol Dis ISSN: 0969-9961 Impact factor: 5.996